Long‐term safety and efficacy of abatacept in children with juvenile idiopathic arthritis

Abstract

Abatacept provided clinically significant and durable efficacy in patients with JIA, including those who did not initially achieve an ACR Pedi 30 response during the initial 4-month open-label lead-in phase.